Results 141 to 150 of about 32,658 (245)

Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2953-2961, April 2026.
Abstract Objective People with chronic kidney disease (CKD) and diabetes are at high risk of cardiovascular disease (CVD). Aortic pulse wave velocity (Ao‐PWV) is an independent predictor of CVD. Cardiovascular outcome trials (CVOTs) with glucagon like peptide‐1 receptor agonist (GLP‐1 RA) class demonstrate notable differences, with lixisenatide having ...
Nikolaos Fountoulakis, Panagiotis Pavlou, Dimitra Stathi, Aicha Goubar, Antonella Corcillo, Maria Flaquer, Salma Ayis, Luigi Gnudi, Janaka Karalliedde   +8 more
wiley   +1 more source

Cholinergic Modulation of Locomotion and Striatal Dopamine Release Is Mediated by α6α4* Nicotinic Acetylcholine Receptors [PDF]

, 2010
Dopamine (DA) release in striatum is governed by firing rates of midbrain DA neurons, striatal cholinergic tone, and nicotinic ACh receptors (nAChRs) on DA presynaptic terminals.
Drenan, Ryan M., Grady, Sharon R., Lester, Henry A., Marks, Michael J., McIntosh, J. Michael, McKinney, Sheri, Miwa, Julie M., Patzlaff, Natalie E., Steele, Andrew D.   +8 more
core  

Comparative effectiveness of combination therapy with SGLT‐2 inhibitors and GLP‐1 RAs compared with SGLT‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3273-3284, April 2026.
Abstract Aims To evaluate the effectiveness of combination therapy with sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) compared with continued SGLT‐2 inhibitor therapy in routine practice among individuals with type 2 diabetes.
Gregor A. Maier, Beata Hennig, Wolfgang Rathmann, Oliver Kuss   +3 more
wiley   +1 more source

Effect of Hormone Replacement Therapy on Liver and Cardiometabolic Outcomes in Peri‐Menopausal MASLD

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. Menopause is associated with increased hepatic fat deposition and thus metabolic dysfunction, contributing to heightened risk of progressive liver and cardiovascular disease.
Alex E. Henney, Jo Wilson, David R. Riley, Uazman Alam, Daniel J. Cuthbertson   +4 more
wiley   +1 more source

Nicotinic Agonist [PDF]

, 2020
openaire   +1 more source

Binding Interactions with the Complementary Subunit of Nicotinic Receptors [PDF]

, 2013
The agonist-binding site of nicotinic acetylcholine receptors (nAChRs) spans an interface between two subunits of the pentameric receptor. The principal component of this binding site is contributed by an α subunit, and it binds the cationic moiety of ...
Blum, Angela P., Dougherty, Dennis A., German, Laurel A., Lester, Henry A., Van Arnam, Ethan B.   +4 more
core  

Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies. [PDF]

Prog Neuropsychopharmacol Biol Psychiatry, 2017
Lewis AS, van Schalkwyk GI, Bloch MH.
europepmc   +1 more source

Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors. [PDF]

Nicotine Tob Res, 2014
Wageman CR, Marks MJ, Grady SR.
europepmc   +1 more source

Putative α7-selective ligands interact with α9-containing nicotinic acetylcholine receptors and modulate immune functions of human mononuclear phagocytes. [PDF]

Front Immunol
Mobasher M, Hone AJ, Pilzecker M, Bozic D, Hecker A, McIntosh JM, Kirschner KN, Grau V, Papke RL, Andleeb H, Richter K.   +10 more
europepmc   +1 more source

Chimeric Approach to Identify Molecular Determinants of Nicotinic Acetylcholine Receptors. [PDF]

Int J Mol Sci
Sapkota P, Akaberi SM, Ghimire B, Sharma K.   +3 more
europepmc   +1 more source